Show simple item record

dc.contributor.authorKumar, Vivek A.
Liu, Qi
Wickremasinghe, Navindee C.
Shi, Siyu
Cornwright, Toya T.
Deng, Yuxiao
Azares, Alon
Moore, Amanda N.
Acevedo-Jake, Amanda M.
Agudo, Noel R.
Pan, Su
Woodside, Darren G.
Vanderslice, Peter
Willerson, James T.
Dixon, Richard A.
Hartgerink, Jeffrey D.
dc.date.accessioned 2017-08-09T17:13:27Z
dc.date.available 2017-08-09T17:13:27Z
dc.date.issued 2016
dc.identifier.citation Kumar, Vivek A., Liu, Qi, Wickremasinghe, Navindee C., et al.. "Treatment of hind limb ischemia using angiogenic peptide nanofibers." Biomaterials, 98, (2016) Elsevier: 113-119. https://doi.org/10.1016/j.biomaterials.2016.04.032.
dc.identifier.urihttps://hdl.handle.net/1911/96642
dc.description.abstract For a proangiogenic therapy to be successful, it must promote the development of mature vasculature for rapid reperfusion of ischemic tissue. Whole growth factor, stem cell, and gene therapies have yet to achieve the clinical success needed to become FDA-approved revascularization therapies. Herein, we characterize a biodegradable peptide-based scaffold engineered to mimic VEGF and self-assemble into a nanofibrous, thixotropic hydrogel, SLanc. We found that this injectable hydrogel was rapidly infiltrated by host cells and could be degraded while promoting the generation of neovessels. In mice with induced hind limb ischemia, this synthetic peptide scaffold promoted angiogenesis and ischemic tissue recovery, as shown by Doppler-quantified limb perfusion and a treadmill endurance test. Thirteen-month-old mice showed significant recovery within 7 days of treatment. Biodistribution studies in healthy mice showed that the hydrogel is safe when administered intramuscularly, subcutaneously, or intravenously. These preclinical studies help establish the efficacy of this treatment for peripheral artery disease due to diminished microvascular perfusion, a necessary step before clinical translation. This peptide-based approach eliminates the need for cell transplantation or viral gene transfection (therapies currently being assessed in clinical trials) and could be a more effective regenerative medicine approach to microvascular tissue engineering.
dc.language.iso eng
dc.publisher Elsevier
dc.rights This is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by Elsevier.
dc.title Treatment of hind limb ischemia using angiogenic peptide nanofibers
dc.type Journal article
dc.citation.journalTitle Biomaterials
dc.subject.keywordHind-limb ischemia
Multi-domain peptide
Peripheral artery disease
Self-assembly
Therapeutic angiogenesis
dc.citation.volumeNumber 98
dc.identifier.digital Treatment_hind_limb_ischemia
dc.type.dcmi Text
dc.identifier.doihttps://doi.org/10.1016/j.biomaterials.2016.04.032
dc.identifier.pmcid PMC4905688
dc.identifier.pmid 27182813
dc.type.publication post-print
dc.citation.firstpage 113
dc.citation.lastpage 119


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record